Shingrix Reviews: Real-World Efficacy and Side Effects

Shingrix is one of the most effective vaccines available for any condition, with a pivotal clinical trial showing it prevented shingles in about 97% of adults over 50. That headline number, combined with strong long-term durability and real-world performance that largely backs up the clinical trials, makes the vaccine’s reputation among infectious disease specialists genuinely enthusiastic. But the reviews from people who have actually received it tell a more textured story, because Shingrix causes noticeably more short-term side effects than most vaccines adults are used to getting.

Clinical Trial Efficacy

The number that defines Shingrix comes from a large randomized trial of adults aged 50 and older, which found overall vaccine efficacy against shingles of 97.2%. That figure held remarkably steady across every age group tested, ranging from 96.6% to 97.9% whether the participants were in their fifties or their eighties.¹ That consistency across ages is unusual for a vaccine and reflects something about how Shingrix works: it uses an adjuvant system that generates strong immune responses even in older immune systems, which tend to respond sluggishly to conventional vaccines.²

Beyond preventing shingles itself, Shingrix also substantially reduces the risk of postherpetic neuralgia, the chronic nerve pain that can persist for months or years after a shingles rash clears. A systematic review and meta-analysis of post-licensure data found two doses of Shingrix were about 76% effective against postherpetic neuralgia.³ That same analysis found the vaccine was roughly two-thirds effective against herpes zoster ophthalmicus, the dangerous form that affects the eye.

Does It Hold Up Outside Clinical Trials

Clinical trials recruit carefully selected participants and monitor them closely, so a fair question is whether Shingrix performs as well in everyday medical practice. The short answer: not quite as spectacularly, but still impressively. A large U.S. study of Medicare beneficiaries in the first two years after Shingrix hit the market found two-dose effectiveness of about 70% against shingles and 76% against postherpetic neuralgia.⁴ That gap between the clinical trial figure and the real-world figure is partly explained by the messiness of real life: people in clinical trials get their doses on a precise schedule, while real-world patients sometimes delay or never receive the second shot. The real-world study also included people over 80 and those with autoimmune or immunosuppressive conditions, populations that are harder to protect, and the vaccine still performed well in those groups.

Studies from other countries echo these findings. A retrospective cohort study in Japan found vaccine effectiveness of about 85% among vaccinated patients compared to matched unvaccinated controls, with protection holding regardless of age.⁵ A U.S. study focused specifically on Chinese American adults aged 50 and older found adjusted effectiveness of roughly 88% against shingles, with zero cases of postherpetic neuralgia in the vaccinated group.⁶ So while Shingrix does not replicate its 97% trial figure in every real-world setting, the evidence consistently shows it prevents most shingles cases and an even larger share of the worst outcomes.

Side Effects People Actually Experience

This is where most personal “reviews” of Shingrix focus, and for good reason. The vaccine is notably more reactogenic than what most adults expect from a routine shot. In pooled clinical trial data, about 78% of Shingrix recipients reported injection site pain, compared to roughly 11% of those who received a placebo. Close to 45% reported muscle aches and fatigue, and about 38% reported headaches.⁷

Those numbers mean a majority of people who get Shingrix will feel something afterward, and a meaningful minority will feel lousy for a day or two. Most of these reactions are mild to moderate and resolve within two to three days. Grade 3 pain at the injection site, meaning pain severe enough to interfere with daily activities, occurred in about 6% of vaccine recipients. Reactions were similar after both the first and second doses, so the common belief that the second shot is dramatically worse than the first is not well supported by the trial data.

There is a sex-based pattern worth knowing about. Women reported side effects after the first dose more frequently than men, roughly 55% versus 36% in one study, though when side effects did occur, their duration was about the same regardless of sex.⁸ This pattern is consistent with broader trends in vaccine immunology and does not indicate a difference in safety or protection.

The reason Shingrix causes more short-term side effects than a typical flu shot is its adjuvant system, which is specifically designed to provoke a strong immune response. The side effects are essentially your immune system doing exactly what the vaccine is asking it to do. That adjuvant-driven reactogenicity is also why the vaccine works so well in older adults, whose immune systems would otherwise mount a tepid response.

The Rare but Serious Concern

Beyond the common, transient side effects, Shingrix carries a boxed warning from the FDA regarding a possible risk of Guillain-Barré syndrome, a rare neurological condition that causes muscle weakness and sometimes temporary paralysis. A study of Medicare beneficiaries found an increased risk of Guillain-Barré syndrome in the weeks after Shingrix vaccination, with an estimated attributable risk of about 3 extra cases per million doses.⁹ To put that in perspective, shingles itself carries its own risk of neurological complications, and 3 per million is an extremely small number against the background of shingles cases prevented.

Post-marketing surveillance data from the Vaccine Adverse Event Reporting System covering 2017 through 2024 identified 145 reports of Guillain-Barré syndrome following Shingrix, including two deaths. That analysis confirmed Guillain-Barré syndrome as a serious but rare adverse event and concluded that patients and clinicians should weigh this risk against the substantial benefits of preventing shingles and its complications.¹⁰ There were no differences in serious adverse events overall between Shingrix and placebo in clinical trials, so the vaccine’s general safety profile remains strong outside of this specific, uncommon risk.

How Long Protection Lasts

One of the biggest unknowns when Shingrix launched was whether its protection would fade quickly, the way the older shingles vaccine’s did. The answer, based on nearly a decade of follow-up data, is encouraging. An extension of the original pivotal trials tracked participants out to an average of about 7 years after vaccination and found efficacy still above 84% during the period from roughly year 5 to year 7. Antibody levels and immune cell counts plateaued at more than six times their pre-vaccination levels and held there.¹¹

A further follow-up pushed the data to nearly 10 years post-vaccination. Efficacy remained above 83% through year 8, then dipped to about 73% in years 9 and 10. When measured across the entire follow-up period from one month after the second dose through nearly 10 years, overall efficacy was 89%.¹² So protection does gradually decline, but even at the 10-year mark, Shingrix is still preventing roughly three out of four shingles cases. Whether a booster dose will eventually be recommended remains an open question, but the current durability data is among the best for any adult vaccine.

How Shingrix Compares to the Older Vaccine

Shingrix replaced Zostavax, a live attenuated vaccine that had been available since 2006. The comparison is not subtle. A network meta-analysis found that in adults 60 and older, Shingrix was about 92% effective against shingles compared to about 51% for the older vaccine. In adults 70 and older, the gap widened even further: roughly 91% for Shingrix versus 37% for Zostavax. Protection against postherpetic neuralgia followed a similar pattern, with Shingrix at about 89% and Zostavax at roughly 66-67%.¹³

The tradeoff is side effects. Shingrix causes significantly more injection site and systemic reactions than Zostavax did. But there were no significant differences in serious adverse events between the two vaccines, meaning the extra discomfort is almost entirely in the temporary, self-resolving category. Zostavax was discontinued in the U.S. in 2020, so the comparison is now academic for anyone getting vaccinated today, but it matters for people who received the old vaccine and wonder whether Shingrix is worth getting on top of it. U.S. and Canadian guidelines recommend Shingrix regardless of prior Zostavax vaccination.¹⁴

Why So Many People Skip the Second Dose

Shingrix requires two doses, ideally given two to six months apart. This is where a practical problem emerges: a substantial number of people get the first dose but never come back for the second. One large analysis of U.S. adults from 2017 through 2021 found that about 72% of people completed the series within six months, and about 86% completed it within two years.¹⁵ That means roughly one in seven people who started the series simply never finished it, even given two full years.

The reasons are a mix of logistical and demographic. Younger adults, those with lower incomes, and those with commercial insurance rather than Medicare were less likely to complete the series. People whose first dose was captured through a pharmacy claim had much higher completion rates (about 74%) than those whose first dose appeared only in medical claims (48%), suggesting that pharmacy-based vaccination programs do a better job of scheduling and reminding patients to return.¹⁶ One dose of Shingrix still provides meaningful protection, with real-world effectiveness around 57%, but two doses are substantially better. If you have had the first dose and are dragging your feet on the second, the data strongly favors going back.

Shingrix for Immunocompromised People

People with weakened immune systems face a much higher risk of shingles and more severe disease when it occurs, so whether Shingrix works in this population is a critical question. Because Shingrix is not a live vaccine, it can safely be given to immunocompromised people, unlike the old Zostavax. A meta-analysis of studies in immunocompromised populations found that Shingrix reduced the incidence of shingles by about 81% across all ages, while also significantly boosting both antibody and cellular immune responses. There was no increase in serious adverse events or deaths compared to placebo, though the vaccine was more reactogenic in terms of common side effects.¹⁷

The vaccine’s immunogenicity has been demonstrated across a range of conditions, including HIV, solid organ transplants, blood cancers, solid tumors, and bone marrow transplant recipients.¹⁸ That said, transplant recipients and people with a history of blood cancers tended to mount somewhat weaker immune responses than other groups. Even when a breakthrough infection does occur in an immunocompromised person who has been vaccinated, there is evidence that the severity of pain and the risk of postherpetic neuralgia are lower than in unvaccinated individuals.¹⁹

Getting Shingrix Alongside Other Vaccines

A common practical question is whether you can get Shingrix at the same visit as a flu shot, pneumonia vaccine, or other routine immunization. The evidence says yes, without meaningful compromise. An overview of co-administration studies found that immune responses to Shingrix were similar whether it was given alone or at the same time as other vaccines, with response rates above 95% in both scenarios. Immune responses to the co-administered vaccines were also non-inferior, with one narrow exception involving a pertussis component.²⁰

The tradeoff, predictably, is more side effects in the short term. Co-administering Shingrix with a pneumococcal vaccine roughly doubled the rate of shivering and fever compared to giving them sequentially. But a post-marketing safety review covering co-administration of Shingrix with influenza vaccines from 2018 through 2024 found no new or unexpected safety signals beyond the known reactogenicity of each vaccine given alone.²¹ If the alternative is missing your second Shingrix dose because you cannot schedule another appointment, combining it with a flu shot at the same visit is a reasonable choice.

Cost and Access as Barriers

For a vaccine with this level of efficacy, Shingrix has a surprisingly uneven uptake problem, and much of it traces back to cost. Out-of-pocket expenses have been identified as a major barrier to shingles vaccination, particularly before recent policy changes.²² In the U.S., the Inflation Reduction Act eliminated cost-sharing for recommended vaccines under Medicare Part D starting in 2023. The effect is visible in the data: Medicare beneficiaries with prescription drug coverage were vaccinated at significantly higher rates than those without, and the gap between the two groups was largest in 2023, the year the policy took effect.²³

For people with private insurance, coverage varies but has generally improved. Most commercial plans now cover Shingrix with no or low copay for adults in the recommended age range, which the CDC sets at 50 and older. If you are under 50 and have a condition that puts you at higher risk, insurance coverage becomes murkier and may require prior authorization. The two-dose series carries a retail price of roughly $300-$400 total without insurance, which is steep enough to explain why cost-sharing barriers have a real effect on who gets vaccinated.

Vaccination After a Shingles Episode

People who have already had shingles often wonder whether the vaccine is still worth getting. The answer is yes. Having shingles once does not prevent recurrence, and Shingrix can reduce the risk of a future episode. The recommended timing is generally to wait until the acute rash has resolved before getting vaccinated. A study of timing for the older live vaccine found that vaccination at various intervals after a shingles episode was safe, with only mild injection site reactions and no cases of rash recurrence during the study period.²⁴ Current CDC guidance for Shingrix follows similar principles, and your immune system can benefit from the vaccine’s boost regardless of whether you have had a prior episode.

The real-world effectiveness data from the Medicare study mentioned earlier included patients with autoimmune conditions and those on immunosuppressive medications, and the vaccine worked in those groups too, which is reassuring for anyone whose prior shingles episode was related to immune compromise. If anything, a prior bout of shingles is an argument for getting vaccinated rather than against it, since it confirms you carry the reactivated virus and your immune system needs the reinforcement.